MY179696A - Compositions and methods comprising bupropion or related compounds and dextromethorphan - Google Patents
Compositions and methods comprising bupropion or related compounds and dextromethorphanInfo
- Publication number
- MY179696A MY179696A MYPI2016701609A MYPI2016701609A MY179696A MY 179696 A MY179696 A MY 179696A MY PI2016701609 A MYPI2016701609 A MY PI2016701609A MY PI2016701609 A MYPI2016701609 A MY PI2016701609A MY 179696 A MY179696 A MY 179696A
- Authority
- MY
- Malaysia
- Prior art keywords
- dextromethorphan
- compositions
- bupropion
- methods
- related compounds
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/13—Amines
- A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
- A61K31/137—Arylalkylamines, e.g. amphetamine, epinephrine, salbutamol, ephedrine or methadone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/13—Amines
- A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
- A61K31/138—Aryloxyalkylamines, e.g. propranolol, tamoxifen, phenoxybenzamine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/485—Morphinan derivatives, e.g. morphine, codeine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/14—Antitussive agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/22—Anxiolytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
Landscapes
- Health & Medical Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- General Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Emergency Medicine (AREA)
- Neurology (AREA)
- Biomedical Technology (AREA)
- Neurosurgery (AREA)
- Pain & Pain Management (AREA)
- Psychiatry (AREA)
- Physiology (AREA)
- Nutrition Science (AREA)
- Rheumatology (AREA)
- Hospice & Palliative Care (AREA)
- Pulmonology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201361900354P | 2013-11-05 | 2013-11-05 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MY179696A true MY179696A (en) | 2020-11-11 |
Family
ID=53042051
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MYPI2016701609A MY179696A (en) | 2013-11-05 | 2014-11-05 | Compositions and methods comprising bupropion or related compounds and dextromethorphan |
Country Status (12)
| Country | Link |
|---|---|
| EP (3) | EP3981403A1 (OSRAM) |
| JP (5) | JP6605485B2 (OSRAM) |
| KR (4) | KR20230148385A (OSRAM) |
| CN (7) | CN113797205A (OSRAM) |
| AU (7) | AU2014346807B2 (OSRAM) |
| CA (4) | CA3175703C (OSRAM) |
| IL (3) | IL298972A (OSRAM) |
| MX (3) | MX373330B (OSRAM) |
| MY (1) | MY179696A (OSRAM) |
| NZ (1) | NZ758428A (OSRAM) |
| SG (4) | SG10201911816XA (OSRAM) |
| WO (1) | WO2015069809A1 (OSRAM) |
Families Citing this family (67)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US11129826B2 (en) | 2013-11-05 | 2021-09-28 | Axsome Therapeutics, Inc. | Bupropion as a modulator of drug activity |
| US11571417B2 (en) | 2013-11-05 | 2023-02-07 | Antecip Bioventures Ii Llc | Bupropion as a modulator of drug activity |
| US11541021B2 (en) | 2013-11-05 | 2023-01-03 | Antecip Bioventures Ii Llc | Bupropion as a modulator of drug activity |
| US11426401B2 (en) | 2013-11-05 | 2022-08-30 | Antecip Bioventures Ii Llc | Bupropion as a modulator of drug activity |
| US11433067B2 (en) | 2013-11-05 | 2022-09-06 | Antecip Bioventures Ii Llc | Bupropion as a modulator of drug activity |
| US11357744B2 (en) | 2013-11-05 | 2022-06-14 | Antecip Bioventures Ii Llc | Bupropion as a modulator of drug activity |
| US11234946B2 (en) | 2013-11-05 | 2022-02-01 | Antecip Bioventures Ii Llc | Bupropion as a modulator of drug activity |
| US11291665B2 (en) | 2013-11-05 | 2022-04-05 | Antecip Bioventures Ii Llc | Bupropion as a modulator of drug activity |
| US11617728B2 (en) | 2013-11-05 | 2023-04-04 | Antecip Bioventures Ii Llc | Bupropion as a modulator of drug activity |
| US11197839B2 (en) | 2013-11-05 | 2021-12-14 | Antecip Bioventures Ii Llc | Bupropion as a modulator of drug activity |
| US11590124B2 (en) | 2013-11-05 | 2023-02-28 | Antecip Bioventures Ii Llc | Bupropion as a modulator of drug activity |
| US11311534B2 (en) | 2013-11-05 | 2022-04-26 | Antecip Bio Ventures Ii Llc | Bupropion as a modulator of drug activity |
| US11576909B2 (en) | 2013-11-05 | 2023-02-14 | Antecip Bioventures Ii Llc | Bupropion as a modulator of drug activity |
| US20220233470A1 (en) | 2013-11-05 | 2022-07-28 | Antecip Bioventures Ii Llc | Bupropion as a modulator of drug activity |
| US11510918B2 (en) | 2013-11-05 | 2022-11-29 | Antecip Bioventures Ii Llc | Bupropion as a modulator of drug activity |
| US11534414B2 (en) | 2013-11-05 | 2022-12-27 | Antecip Bioventures Ii Llc | Bupropion as a modulator of drug activity |
| US11123344B2 (en) | 2013-11-05 | 2021-09-21 | Axsome Therapeutics, Inc. | Bupropion as a modulator of drug activity |
| US11253492B2 (en) | 2013-11-05 | 2022-02-22 | Antecip Bioventures Ii Llc | Bupropion as a modulator of drug activity |
| US11147808B2 (en) | 2013-11-05 | 2021-10-19 | Antecip Bioventures Ii Llc | Method of decreasing the fluctuation index of dextromethorphan |
| US11382874B2 (en) | 2013-11-05 | 2022-07-12 | Antecip Bioventures Ii Llc | Bupropion as a modulator of drug activity |
| US11571399B2 (en) | 2013-11-05 | 2023-02-07 | Antecip Bioventures Ii Llc | Bupropion as a modulator of drug activity |
| US11207281B2 (en) | 2013-11-05 | 2021-12-28 | Antecip Bioventures Ii Llc | Bupropion as a modulator of drug activity |
| US11524007B2 (en) | 2013-11-05 | 2022-12-13 | Antecip Bioventures Ii Llc | Bupropion as a modulator of drug activity |
| WO2016081027A1 (en) * | 2014-11-21 | 2016-05-26 | Antecip Bioventures Ii Llc | Methods of modulating drug plasma levels using erythrohydroxybupropion |
| US11576877B2 (en) | 2013-11-05 | 2023-02-14 | Antecip Bioventures Ii Llc | Bupropion as modulator of drug activity |
| US11344544B2 (en) | 2013-11-05 | 2022-05-31 | Antecip Bioventures Ii Llc | Bupropion as a modulator of drug activity |
| US11478468B2 (en) | 2013-11-05 | 2022-10-25 | Antecip Bioventures Ii Llc | Bupropion as a modulator of drug activity |
| US11229640B2 (en) | 2013-11-05 | 2022-01-25 | Antecip Bioventures Ii Llc | Combination of dextromethorphan and bupropion for treating depression |
| US11541048B2 (en) | 2013-11-05 | 2023-01-03 | Antecip Bioventures Ii Llc | Bupropion as a modulator of drug activity |
| US11617747B2 (en) | 2013-11-05 | 2023-04-04 | Antecip Bioventures Ii Llc | Bupropion as a modulator of drug activity |
| US11253491B2 (en) | 2013-11-05 | 2022-02-22 | Antecip Bioventures Ii Llc | Bupropion as a modulator of drug activity |
| US11426370B2 (en) | 2013-11-05 | 2022-08-30 | Antecip Bioventures Ii Llc | Bupropion as a modulator of drug activity |
| US20200338022A1 (en) | 2019-01-07 | 2020-10-29 | Antecip Bioventures Ii Llc | Bupropion as a modulator of drug activity |
| US12109178B2 (en) | 2013-11-05 | 2024-10-08 | Antecip Bioventures Ii Llc | Bupropion as a modulator of drug activity |
| US11497721B2 (en) | 2013-11-05 | 2022-11-15 | Antecip Bioventures Ii Llc | Bupropion as a modulator of drug activity |
| US11596627B2 (en) | 2013-11-05 | 2023-03-07 | Antecip Bioventures Ii Llc | Bupropion as a modulator of drug activity |
| US11273133B2 (en) | 2013-11-05 | 2022-03-15 | Antecip Bioventures Ii Llc | Bupropion as a modulator of drug activity |
| US11191739B2 (en) | 2013-11-05 | 2021-12-07 | Antecip Bioventures Ii Llc | Bupropion as a modulator of drug activity |
| IL298972A (en) * | 2013-11-05 | 2023-02-01 | Antecip Bioventures Ii Llc | Preparations containing dextromethorphan and bupropion or similar substances and their uses |
| US11364233B2 (en) | 2013-11-05 | 2022-06-21 | Antecip Bioventures Ii Llc | Bupropion as a modulator of drug activity |
| US11285118B2 (en) | 2013-11-05 | 2022-03-29 | Antecip Bioventures Ii Llc | Bupropion as a modulator of drug activity |
| US11419867B2 (en) | 2013-11-05 | 2022-08-23 | Antecip Bioventures Ii Llc | Bupropion as a modulator of drug activity |
| US12194006B2 (en) | 2013-11-05 | 2025-01-14 | Antecip Bioventures Ii Llc | Bupropion as a modulator of drug activity |
| US11517543B2 (en) | 2013-11-05 | 2022-12-06 | Antecip Bioventures Ii Llc | Bupropion as a modulator of drug activity |
| US11298352B2 (en) | 2013-11-05 | 2022-04-12 | Antecip Bioventures Ii Llc | Bupropion as a modulator of drug activity |
| US11969421B2 (en) | 2013-11-05 | 2024-04-30 | Antecip Bioventures Ii Llc | Bupropion as a modulator of drug activity |
| US11439636B1 (en) | 2013-11-05 | 2022-09-13 | Antecip Bioventures Ii Llc | Bupropion as a modulator of drug activity |
| US11298351B2 (en) | 2013-11-05 | 2022-04-12 | Antecip Bioventures Ii Llc | Bupropion as a modulator of drug activity |
| TW202106301A (zh) * | 2014-09-14 | 2021-02-16 | 美商阿瓦尼爾製藥股份有限公司 | 用於治療失智症中躁動行為之包含右旋美索芬(dextromethorphan)化合物及奎尼丁(quinidine)的藥學組成物 |
| EP4360628A3 (en) * | 2016-03-24 | 2024-10-23 | Antecip Bioventures II LLC | Compositions and methods for increasing the metabolic lifetime of dextromethorphan and related pharmacodynamic effects |
| TWI795446B (zh) * | 2017-10-04 | 2023-03-11 | 美商神經治療股份有限公司 | 右旋美索芬(dextromethorphan)經皮輸送裝置 |
| US20230225995A1 (en) * | 2019-01-07 | 2023-07-20 | Antecip Bioventures Ii Llc | Combination of dextromethorphan and bupropion for treating depression |
| CN114712358A (zh) * | 2019-01-07 | 2022-07-08 | 安泰赛普生物风投二代有限责任公司 | 用于治疗抑郁症的右美沙芬和安非他酮的组合 |
| CA3179048A1 (en) * | 2020-03-30 | 2021-10-07 | Antecip Bioventures Ii Llc | Use of bupropion and dextromethorphan combinations for treating neurological disorders |
| US12433884B2 (en) | 2020-06-05 | 2025-10-07 | Antecip Bioventures Ii Llc | Compounds and combinations thereof for treating neurological and psychiatric conditions |
| US12472156B2 (en) | 2020-06-05 | 2025-11-18 | Antecip Bioventures Ii Llc | Compounds and combinations thereof for treating neurological and psychiatric conditions |
| CN114340608B (zh) * | 2020-07-20 | 2023-10-31 | 深圳信立泰药业股份有限公司 | 一种药物组合物及其应用 |
| JP2023553393A (ja) | 2020-12-01 | 2023-12-21 | アンテシップ バイオベンチャーズ トゥー エルエルシー | うつ病患者の自殺リスク低減のためのブプロピオンおよびデキストロメトルファン |
| KR20230131927A (ko) * | 2021-01-18 | 2023-09-14 | 안테씨프 바이오벤쳐스 투 엘엘씨 | 신경 정신 질환에 대한 항우울제와 덱스트로메토르판의조합 |
| CN112999350A (zh) * | 2021-02-23 | 2021-06-22 | 北京斯利安药业有限公司 | 一种药物组合物、复方制剂及其制备方法与应用 |
| US11717518B1 (en) | 2022-06-30 | 2023-08-08 | Antecip Bioventures Ii Llc | Bupropion dosage forms with reduced food and alcohol dosing effects |
| CN118785900A (zh) * | 2022-06-30 | 2024-10-15 | 艾克萨姆治疗公司 | 包含安非他酮和半胱氨酸的药物组合物 |
| US12036191B1 (en) | 2022-06-30 | 2024-07-16 | Antecip Bioventures Ii Llc | Treatment of poor metabolizers of dextromethorphan with a combination of bupropion and dextromethorphan |
| US12156914B2 (en) | 2022-06-30 | 2024-12-03 | Axsome Therapeutics, Inc. | Pharmaceutical compositions comprising bupropion and cysteine |
| US12194036B2 (en) | 2022-07-07 | 2025-01-14 | Antecip Bioventures Ii Llc | Combination of dextromethorphan and bupropion for treating depression |
| US11730706B1 (en) | 2022-07-07 | 2023-08-22 | Antecip Bioventures Ii Llc | Treatment of depression in certain patient populations |
| US11844797B1 (en) | 2023-04-20 | 2023-12-19 | Antecip Bioventures Ii Llc | Combination of dextromethorphan and bupropion for treating depression |
Family Cites Families (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5350756A (en) * | 1991-06-17 | 1994-09-27 | Smith Richard A | Use of a cytochrome oxidase inhibitor to increase the cough-suppressing activity of dextromorphan |
| EP0980247A1 (en) * | 1997-05-07 | 2000-02-23 | Algos Pharmaceutical Corporation | Composition and method combining an antidepressant with an nmda receptor antagonist, for treating neuropathic pain |
| US6207674B1 (en) * | 1999-12-22 | 2001-03-27 | Richard A. Smith | Dextromethorphan and oxidase inhibitor for weaning patients from narcotics and anti-depressants |
| US6780871B2 (en) * | 2001-01-29 | 2004-08-24 | Albany Medical College | Methods and compositions for treating addiction disorders |
| TWI326214B (en) * | 2002-07-17 | 2010-06-21 | Avanir Pharmaceuticals Inc | Pharmaceutical compositions comprising dextromethorphan and quinidine for the treatment of neurological disorders |
| JP2009525343A (ja) * | 2006-02-03 | 2009-07-09 | アバニール・ファーマシューティカルズ | 鬱病、不安および神経変性疾患を治療するためのデキストロメトルファンおよびキニジンを含む薬剤組成物 |
| WO2009006194A1 (en) * | 2007-06-28 | 2009-01-08 | Avanir Pharmaceuticals | Pharmaceutical compositions for the treatment of involuntary emotional expression disorder |
| WO2012118562A1 (en) * | 2011-03-02 | 2012-09-07 | Rhine Pharmaceuticals, Llc | Compositions and methods for treating depression, adhd and other central nervous system disorders employing novel bupropion compounds, and methods for production and use of novel bupropion compounds and formulations |
| US20130274282A1 (en) * | 2012-04-16 | 2013-10-17 | Herriot Tabuteau | Compositions and methods comprising celecoxib or related compounds and dextromethorphan |
| IL298972A (en) * | 2013-11-05 | 2023-02-01 | Antecip Bioventures Ii Llc | Preparations containing dextromethorphan and bupropion or similar substances and their uses |
-
2014
- 2014-11-05 IL IL298972A patent/IL298972A/en unknown
- 2014-11-05 CN CN202111061803.4A patent/CN113797205A/zh active Pending
- 2014-11-05 EP EP21191390.0A patent/EP3981403A1/en active Pending
- 2014-11-05 SG SG10201911816XA patent/SG10201911816XA/en unknown
- 2014-11-05 KR KR1020237034772A patent/KR20230148385A/ko active Pending
- 2014-11-05 CA CA3175703A patent/CA3175703C/en active Active
- 2014-11-05 JP JP2016552474A patent/JP6605485B2/ja active Active
- 2014-11-05 MY MYPI2016701609A patent/MY179696A/en unknown
- 2014-11-05 MX MX2016005867A patent/MX373330B/es active IP Right Grant
- 2014-11-05 CA CA2929415A patent/CA2929415C/en active Active
- 2014-11-05 CA CA3154845A patent/CA3154845C/en active Active
- 2014-11-05 KR KR1020217016618A patent/KR20210068157A/ko not_active Ceased
- 2014-11-05 MX MX2020004075A patent/MX388666B/es unknown
- 2014-11-05 SG SG10201911808QA patent/SG10201911808QA/en unknown
- 2014-11-05 CN CN201480072191.0A patent/CN106163522A/zh active Pending
- 2014-11-05 EP EP14859589.5A patent/EP3065742A4/en active Pending
- 2014-11-05 WO PCT/US2014/064184 patent/WO2015069809A1/en not_active Ceased
- 2014-11-05 AU AU2014346807A patent/AU2014346807B2/en active Active
- 2014-11-05 NZ NZ758428A patent/NZ758428A/en unknown
- 2014-11-05 CN CN201910649199.3A patent/CN110251517A/zh active Pending
- 2014-11-05 KR KR1020167013970A patent/KR102264179B1/ko active Active
- 2014-11-05 EP EP21191393.4A patent/EP3981404A1/en active Pending
- 2014-11-05 CN CN201910649207.4A patent/CN110279682A/zh active Pending
- 2014-11-05 KR KR1020227013910A patent/KR102603013B1/ko active Active
- 2014-11-05 SG SG11201603391XA patent/SG11201603391XA/en unknown
- 2014-11-05 CA CA3256217A patent/CA3256217A1/en active Pending
- 2014-11-05 CN CN202111061795.3A patent/CN113750099A/zh active Pending
- 2014-11-05 SG SG10201810888XA patent/SG10201810888XA/en unknown
- 2014-11-05 CN CN202111061009.XA patent/CN113750098A/zh active Pending
- 2014-11-05 CN CN201910649198.9A patent/CN110327338A/zh active Pending
-
2016
- 2016-05-04 MX MX2021015234A patent/MX2021015234A/es unknown
- 2016-05-05 IL IL245504A patent/IL245504B/en active IP Right Grant
-
2018
- 2018-05-23 AU AU2018203638A patent/AU2018203638C1/en active Active
-
2019
- 2019-09-23 AU AU2019236614A patent/AU2019236614C1/en active Active
- 2019-10-16 JP JP2019189318A patent/JP6927601B2/ja active Active
- 2019-12-04 AU AU2019275593A patent/AU2019275593B2/en active Active
-
2021
- 2021-04-23 AU AU2021202497A patent/AU2021202497B2/en active Active
- 2021-06-07 IL IL283760A patent/IL283760B2/en unknown
- 2021-07-29 JP JP2021124094A patent/JP2021169527A/ja active Pending
-
2023
- 2023-06-01 AU AU2023203438A patent/AU2023203438B2/en active Active
- 2023-07-27 JP JP2023122146A patent/JP2023129646A/ja active Pending
-
2025
- 2025-09-12 AU AU2025230795A patent/AU2025230795A1/en active Pending
- 2025-09-26 JP JP2025160293A patent/JP2025175199A/ja active Pending
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| MY179696A (en) | Compositions and methods comprising bupropion or related compounds and dextromethorphan | |
| PH12016500511A1 (en) | Selective grp94 inhibitors and uses thereof | |
| TW201613887A (en) | Antiproliferative compounds and methods of use thereof | |
| UA117451C2 (uk) | Терапевтично активні сполуки і способи їх застосування | |
| WO2014113429A3 (en) | Substituted pyrrolopyrimidine compounds, compositions thereof, and methods of treatment therewith | |
| MX2015016983A (es) | Moduladores del transporte nuclear y usos de los mismos. | |
| WO2015056094A3 (en) | Pharmaceutical composition comprising a trpa1 antagonist and an analgesic agent | |
| MD20160007A2 (ro) | Inhibitori ai RORC2 şi metode de utilizare a acestora | |
| WO2015058664A8 (zh) | 淫羊藿苷元在制备预防或治疗血细胞减少药物中的用途 | |
| EA201691918A1 (ru) | Фармацевтические составы ингибитора киназ семейства raf, способы их получения и способы их применения | |
| HK1218251A1 (zh) | 用拉喹莫德治疗多发性硬化症 | |
| NZ702415A (en) | Methods for treating neutropenia using retinoid agonists | |
| MX2016007370A (es) | Agente terapeutico y/o preventivo que comprende un derivado de 1-indansulfamida para el dolor. | |
| NZ722600A (en) | Methods of treating mild brain injury | |
| SG10201907291QA (en) | Monomethylfumarate prodrug compositions | |
| AU2016216741A1 (en) | Compositions and methods of use of an inappetance-controlling compound | |
| TN2019000032A1 (en) | Pharmaceutical compositions and uses directed to lysosomal storage disorders | |
| MX2018014129A (es) | Composiciones farmaceuticas de oligomero de morfolino fosforodiamidato. | |
| MX2020001428A (es) | Composiciones de grapiprant y metodos para usar las mismas. | |
| WO2015027121A3 (en) | Cancer treatment | |
| MX2014014814A (es) | Composicion farmaceutica para el tratamiento de inflamacion y dolor. | |
| SG10201809673RA (en) | Treatment of androgen deprivation therapy associated symptoms | |
| MX2014014816A (es) | Composicion farmaceutica para tratar inflamacion y dolor. | |
| MX365021B (es) | Composicion para tratar o prevenir enfermedades ocasionadas por permeabilidad vascular, que contiene como ingrediente activo imatinib o una sal farmaceuticamente aceptable del mismo. | |
| IN2013MU03428A (OSRAM) |